Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | The fundamentals of de-escalation in oncology

Michiel Strijbos • 9 Sep 2022
ESMO 2022
General

Michiel Strijbos, MD, GasthuisZusters Antwerpen, Antwerp, Belgium, discusses the increasing importance of the de-escalation of chemotherapy to maintain patients’ quality of life whilst maintaining good survival outcomes. The European Society for Medical Oncology (ESMO) has generated a framework on how to approach de-escalation, including strategies such as biomarkers and imaging. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Michiel Strijbos

1:12
The rise of de-escalation strategies in cancer care
Michiel Strijbos • 9 Sep 2022
0:30
What to look forward to in GU at ESMO 2022?
Michiel Strijbos • 9 Sep 2022

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals